Abstract
Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.
Objective: An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.
Results: In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.
Conclusions: The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.
Keywords: Glaucoma, anti-glaucoma drugs, intraocular pressure, retinal ganglion cells, purinergic ligands, Rho kinase inhibitors, dopamine ligands, nitric oxide, histone deacetylase inhibitors.
Graphical Abstract
Current Neuropharmacology
Title:Novel Therapeutics in Glaucoma Management
Volume: 16 Issue: 7
Author(s): Claudio Bucolo*, Chiara Bianca Maria Platania, Filippo Drago, Vincenza Bonfiglio, Michele Reibaldi, Teresio Avitabile and Maurizio Uva
Affiliation:
- Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania,Italy
Keywords: Glaucoma, anti-glaucoma drugs, intraocular pressure, retinal ganglion cells, purinergic ligands, Rho kinase inhibitors, dopamine ligands, nitric oxide, histone deacetylase inhibitors.
Abstract: Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.
Objective: An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.
Results: In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.
Conclusions: The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.
Export Options
About this article
Cite this article as:
Bucolo Claudio *, Platania Bianca Maria Chiara, Drago Filippo , Bonfiglio Vincenza , Reibaldi Michele, Avitabile Teresio and Uva Maurizio, Novel Therapeutics in Glaucoma Management, Current Neuropharmacology 2018; 16 (7) . https://dx.doi.org/10.2174/1570159X15666170915142727
DOI https://dx.doi.org/10.2174/1570159X15666170915142727 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications
Current Cardiology Reviews Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued) Structure Activity Relationships for Nicotinamide in the Treatment of Stroke
Letters in Drug Design & Discovery Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets The Role of Coronary Physiology in Contemporary Percutaneous Coronary Interventions
Current Cardiology Reviews Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Sodium Oleate Increases Ampicillin Sensitivity in Methylophilus quaylei Biofilms on Teflon and Polypropylene
Current Pharmaceutical Biotechnology Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery miR-666-3p Mediates the Protective Effects of Mesenchymal Stem Cell-derived Exosomes Against Oxygen-glucose Deprivation and Reoxygenation- induced Cell Injury in Brain Microvascular Endothelial Cells via Mitogen-activated Protein Kinase Pathway
Current Neurovascular Research Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Recent Advances in the Design of Iron Chelators Against Oxidative Damage
Mini-Reviews in Medicinal Chemistry Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome
Recent Advances in Inflammation & Allergy Drug Discovery